CV Therapeutics, es geht wieder los! - 500 Beiträge pro Seite

[f f]

bei erfolgreicher Zulassung ihres Medikamentes geht es um Auftragswerte
von 800 bis 900 Mill. US Dolar!

Die drei vorgeschriebenen Test sind
soweit bekannt erfolgreich bestanden.

f f

[SirToby]

Hast Du Dich mit dem Wert näher beschäftigt? Ich beobachte ihn schon seit einiger Zeit, hatte aber bisher nie die Zeit für eine in-depth-analyse. Bin daher für mehr infos ganz dankbar.

[f f]

Nein leider nicht, bin über NTV auf den
Wert aufmerksam geworden. Bin auch für jede Info dankbar.

f f

[LordAT]

Vereins- und Westbank empfiehlt CW Therapeutics zum Kauf, genau wie der Aktionär. Bernd Förtsch hat schon verkündet in der nächsten Ausgabe des Aktionärs die Aktie näher zu besprechen. Das Unternehmen ist fundamental sehr gut abgesichert (kaum Risiko), hat aber ein gewaltiges, kurzfristiges Kurspotential. 90 EUR bis zum Juni halte ich für möglich.

[Batavier]

Ich habe den Namen dieser Firma erst vor kurzem erstmals gelesen. Vielleicht (wahrscheinlich nicht) ist dieser Artikel für Euch noch neu:American Heart Association Selects CV Therapeutics` Discovery of Role Of `Good` Cholesterol-Regulating Gene as Top Ten 1999 Research Advances In Heart Disease
Monday, January 3, 2000 07:00 AM Mail this article to a friend

CVT and Incyte Demonstrate the Benefits of Genomics and Microarry Analysis To Drug Discovery
PALO ALTO, Calif., Jan. 3 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX, news, msgs) and Incyte Pharmaceuticals, Inc. (Nasdaq: INCY, news, msgs) announced that the American Heart Association has selected CV Therapeutics` discovery of the role of the "good" cholesterol-regulating gene, ABC1, as one of the top ten 1999 research advances in heart disease and stroke. This discovery was presented at the American Heart Association`s 72nd Scientific Sessions and published in the Journal of Clinical Investigation in 1999.

Through the use of Incyte`s gene expression microarray technology along with other techniques, scientists at CV Therapeutics, working with Incyte and University of Washington, identified that ABC1 is a key gene involved in the formation of high density lipoprotein (HDL), or "good" cholesterol. Richard M. Lawn, Ph.D., Vice President, Discovery Research at CV Therapeutics and his colleagues at CVT then demonstrated that increasing levels of this gene in cultured cells in the laboratory enhances the removal of cholesterol from cultured cells. These discoveries provided the first biological evidence suggesting that drug therapies that increase the level of ABC1 might aid in the removal of cholesterol from the body, holding the potential for reducing the risk of heart disease among the general population.

According to the American Heart Association, the annual list was first created in 1996 to highlight the achievements in basic and clinical research that may have the greatest impact in improving the prevention and treatment of cardiovascular disease, the nation`s number one killer.

"The American Heart Association`s recognition is testimony to the potential this finding holds for discovering new therapeutic solutions for HDL cholesterol management," said Louis G. Lange, M.D., Ph.D., Chairman and Chief Executive Officer of CV Therapeutics. "This discovery demonstrates how combining cardiovascular expertise along with the power of genomics and microarray technology can lead to new drug discovery targets that could potentially help the many people suffering from cardiovascular diseases."

This discovery also represented the first time gene expression microarray analysis has been used to identify a defect associated with a human genetic condition. This technique uses a micro-chip with thousands of genes covering its surface. Microarray analysis dramatically reduces the amount of time usually necessary to monitor the expression level of thousands of genes concurrently. Scientists were able to pinpoint the faulty gene and its encoded protein with the help of Incyte`s Gene Album(TM) microarrays by studying the activity of 60,000 genes from people with Tangier disease, a rare genetic disorder that results in dangerously low levels of HDL, and an increased risk for heart attack, against genes from an unaffected individual.

"This is a validation of the role of genomics in the understanding and treatment of disease," said Randy Scott, President and Chief Scientific Officer of Incyte Pharmaceuticals. "We are appreciative of the acknowledgement by the American Heart Association and would welcome future collaboration opportunities with CV Therapeutics."

The CV Therapeutics and Incyte collaboration is focused on creating gene expression profiles of cardiovascular disease models. CV Therapeutics contributes its molecular cardiology expertise and Incyte contributes its genomics expertise to the collaboration.

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, uncertainties related to CV Therapeutics` early stage of development and clinical trials. Actual results could differ materially. Factors that could cause or contribute to such differences are more fully discussed in CV Therapeutics` Prospectus dated October 6, 1999.

Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte`s SEC reports, including its Annual Report on Form 10-Q for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements.

CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CVT currently has three drug candidates in clinical trials. Ranolazine, the first in a new class of drugs known as partial fatty acid oxidation (pFOX) inhibitors for the potential treatment of angina, is in Phase III clinical trials. CVT-510, for the potential treatment of atrial arrhythmias, is in Phase II clinical trials. A third product, CVT-124, for the potential treatment of congestive heart failure (CHF), is in Phase II clinical trials. For more information, please visit CV Therapeutics` web site at www.cvt.com.

Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte`s Web site at www.incyte.com

SOURCE CV Therapeutics, Inc.; Incyte Pharmaceuticals, Inc.

CONTACT: Dan Spiegelman, SVP & Chief Financial Officer, 650-812-9509, Christopher Chai, Treasurer & Director, Investor Relations, 650-812-9560, both of CV Therapeutics, or media, Carol Harrison, 212-453-2442, for CV Therapeutics; or Teresa Gaines, VP, Corporate Communications of Incyte Pharmaceuticals, 510-206-7257

[Midas2000]

Hallo LordAT,

90 $ und weit mehr kann ich mir gut vorstellen, falls es zur Zulassung ihres Produktes Ranolazine (derzeit in Phase III) kommt. Aber `kaum Risiko` trifft die Sachlage kaum! Es gibt kaum ein riskanteres Investment als ein Biotechunternehmen, daß noch kein einziges zugelassenes Produkt hat.
Ich bin auch mit einem kleinen Betrag investiert, aber man sollte sich des Risikos schon bewußt sein. Kommt es zur Zulassung von Ranolazine, sind enorme Gewinne zu erwarten. Falls nicht (und die Chancen stehen bei Phase III etwa 50:50) fällt der Wert mindestens auf 20, wenn nicht 10 $ zurück.

[LordAT]

HEUTE WURDE ES BEKANN (jedenfalls mir erst heute: Ranzoline ist zugelassen!!! Kurz darauf veröffentlichte der Neue Markt Online Newsletter eine Kaufempfehlung mit dem Kursziel 100 EUR.

[SirToby]

Wo findet man dazu eine Mitteilung? Ich habe nirgendwo etwas gelesen, und soweit ich weiß steht die Zulassung erst in Zukunft an. Nächster Event sind weitere Testergebnisse im März...woher also die Info bezüglich einer Zulassung?

[Spoke]

Ich hab auch nichts gefunden, hatte aber auch nicht so wahnsinnig Zeit. War ja dann auch ne schöne Steigerung gestern

Was meint ihr ist heute los, Gewinnmitnahmen ? (Aktuell -4,47%)
Naja, das wird schon.

MfG Spoke

[Spoke]

Hallo ?

News, Zahlen, Fakten ?

[tincap]

news habe ich keine aber ich freue mich über den weiteren kursantieg
heute schon mal bei 51,--€ gewesen
das kz von hordenbach (100,--€) schaffen wir eher als gedacht

[bioscope]

Sehr volatil. Heute schon wieder -6% an der Nasdaq eroeffnet.

[Rubininvest]

????? PIPELINE CVTX ?????

Hallo ,wer weiss was mit CVTX`s Pipeline passiert ist ?!
Laut Webside sind 3 Präperate in klinischen Tests:
1) Ranolanzine
2) CVT-124
3) CVT-510

Was ist mit CVT-1 (Phase 2, reduce LDL cholesterol) und mit CVT-E002 (Phase1)
passiert ???

Wenn mich nicht alles täuscht wäre doch gerade CVT-1 als Atherosclerosis
Medikament in Frage gekommen ,ein 8 Milliarden $$$ Markt ,ohne adequate
Behandlungsmethode bisher (ausser Lipitor), schade eigentlich ,ist das
Ding terminiert worden oder was ,wieso krieg ich keine Infos ,wer hat
welche... Danke!

Regards
Rubininvest

[peachkiller]

Schreibe doch mal an

[e-mail]

Das habe ich auch gemacht. Es kam aber noch keine Antwort.
gruß pm

[yogi03]

hallo cv fans,
was gibt es für news ?
warum ist der kurs heute so nach oben geschnellt?
weis jemand bescheid?
lohnt es sich zum nachkaufen?
welche kursziele peilt ihr für die nächsten 2-3 monate an?
DANKE für alle antworten!

[peachkiller]

Hm, interessante Aktie...

...macht in nur 3 Wochen 80%. (am 28.Jan 36EUR)
Und Keiner weiß warum und nur wenige interessieren sich hier im Board dafür!

Faszinierend!
pm

[JoeLo]

Hat denn niemand den Biotech-Report im Abo? Dann wüßtet ihr was mit CV Therap. ist!
Mir ist der Biotech-Report auf Dauer zu teuer! Wer ihn weiterhin im Abo hat bitte Bescheid geben. Danke!
Weitere Tipps:

- Aradigm
- Immune Response
- Ilex
- Nanogen
- Neoforma
- Celgene


Da geht was! Der Biotech-Report ist Gold wert!!!

[nautilus]

hallo joelo,
wo gibts den report ??? abo ??

nautilus

[peachkiller]

Biogen and CV Therapeutics Say Adenosine A1 Antagonist is Successful In A Phase II Trial

CAMBRIDGE, Mass., and PALO ALTO, Calif., Feb. 17 /PRNewswire/ --
Biogen, Inc. (Nasdaq: BGEN) and CV Therapeutics, Inc. (Nasdaq: CVTX) today
announced that Biogen`s adenosine A1 antagonist/CVT-124 compound successfully
completed a Phase II trial in patients with moderate-to-severe Congestive
Heart Failure (CHF). Biogen said it would continue studies with its lead
backup molecule.
Jim Vincent, Biogen`s Chairman and Chief Executive Officer, said, "This
Phase II trial validates the potential of this adenosine pathway in the
cardio-renal syndrome that makes CHF such a deadly disease. We achieved
statistical significance on key clinical endpoints and are very pleased with
what we have learned about this pathway in our studies during the past three
years. With this extensive experience, we believe we can make significant
progress with this program as we move it through the clinic."
Adenosine A1 antagonist/CVT-124 is a highly selective small molecule
adenosine A1 receptor antagonist that targets receptors in the kidney that are
clinically relevant for the treatment of CHF. The Phase II trial was a
randomized, double-blinded, placebo-controlled, dose-ranging study of the
molecule in moderate-to-severe heart failure patients used in conjunction with
standard therapies.
Biogen said it will make a milestone payment to CV Therapeutics, from
which it licensed the program.
In addition to historical information, this press release contains
forward-looking statements within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. Reference is made in
particular to statements regarding continuation of clinical studies of a new
adenosine A1 antagonist molecule and the expected progress of such studies.
These statements are based on the Companies` current beliefs and expectations
as to such future outcomes. Factors which could cause actual results to
differ materially from the Companies` current expectations include the risk
that the new molecule to be studied will not yield the same clinical results
as the molecule that was the subject of the completed Phase II trial or that
problems or delays may arise during preparations for future clinical trials or
in the conduct of such trials or that problems may arise with respect to
toxicology, formulation of manufacturing of the new molecule, as well as the
other risks and uncertainties described from time to time in the Companies`
periodic reports filed with the Securities and Exchange Commission. Drug
development involves a high degree of risk. Success in early stage clinical
trials does not ensure that later stage or larger scale clinical trials will
be successful.
Biogen, Inc., winner of the 1998 U.S. National of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company`s revenues are generated from worldwide sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products.
Biogen`s research and development activities are focused on novel products for
multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular
diseases and in developmental biology and gene therapy. For copies of press
releases and additional information about the Company, please consult Biogen`s
Homepage on the World Wide Web at http://www.biogen.com .
CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CVT is currently conducting
clinical studies for two of its products. Ranolazine, the first in a new
class of drugs known as partial fatty acid oxidation (pFOX) inhibitors for the
potential treatment of angina, is in Phase III clinical trials. CVT-510, for
the potential treatment of atrial arrhythmias, is in Phase II clinical trials.
For more information, please visit CV Therapeutics` web site at http://www.cvt.com.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[peachkiller]

CV Therapeutics Announces Proposed Issuance of Convertible Subordinated Notes

PALO ALTO, Calif., Feb. 25 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it intends to issue
$125.0 million aggregate principal amount of convertible subordinated notes
($143.8 million if the over-allotment option is exercised in full).
It intends to sell the notes in a private offering to qualified
institutional buyers under Rule 144A of the Securities Act of 1933, as
amended. The notes will be convertible into shares of CV Therapeutics` common
stock and will have a seven-year term.
The net proceeds of the offering will be used by CV Therapeutics to fund
clinical trials, preclinical studies, research and development activities,
working capital and general corporate purposes. The offering is subject to
market conditions and other factors.
The notes to be offered will not be registered under the Securities Act or
applicable state securities laws, and may not be offered or sold in the United
States absent registration under the Securities Act and applicable state
securities laws or available exemptions from the registration requirements.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to the offering of the notes and the
application of proceeds from the proposed offering. Actual results could
differ materially.




SOURCE CV Therapeutics, Inc.
Web Site: http://www.cvt.com

[e4 sf6]

Peachkiller,

Hey ,ich bin`s nochmal ,Rubininvest ,hast du eine Antwort von CVTX
bekommen bezueglich CVT-1 und CVT-E002 ?

[nautilus]

Hi Peachkiller!

ich hasse blonde rosa gekleidete kartfahrende Prinzessinenfuts!!!!
es lebe mariokart

[peachkiller]

Rubininvest: Nein, leider noch nicht!
nautilus: Das hast Du schön gesagt, aber was habe ich damit zu tun?
pm